Competing Health Risks Associated with the COVID-19 Pandemic and Response: A Scoping Review

Stefan Baral[1], Amrita Rao[1], Jean Olivier Twahirwa Rwema[1], Carrie Lyons[1], Muge Cevik[2], Anna E. Kågesten[3], Daouda Diouf[4], Annette H. Sohn[5], Refilwe Phaswana-Mafuya[6], Adeeba Kamarulzaman[7], Gregorio Millett[8], Julia L. Marcus[9], Sharmistha Mishra[10]

Author Affiliations

1) Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD
2) Division of Infection and Global Health Research, School of Medicine, University of St. Andrews, Scotland
3) Department of Global Public Health, Karolinska Institutet, Sweden
4) Enda Santé, Dakar, Senegal
5) TREAT Asia, amfAR, the Foundation for AIDS Research, Bangkok, Thailand
6) University of Johannesburg, South Africa
7) University of Malaya, Kuala Lumpur, Malaysia
8) Public Policy Office, amfAR, Washington DC
9) Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA
10) Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada

Disclosures

Annette Sohn and Gregorio Millett report funding from Viiv. Julia Marcus has consulted in the past for Kaiser Permanente Northern California on a research grant from Gilead Sciences. All other authors report no competing interests.

Funding

Amrita Rao is supported in part by the National Institute of Mental Health [F31MH124458]. Julia Marcus is supported in part by the National Institute of Allergy and Infectious Diseases [K01AI122853].

Author Contributions

The article was conceptualized by SB, AR, JOT, and CL. SB led manuscript development. AR, JOT, CL led the literature reviews with AR synthesizing literature for HIV, JOT for malnutrition, CL for malaria, MC for tuberculosis, and AEK for selected sexual and reproductive health outcomes. AHS led writing of global research agenda, GM on policy, and SM on mathematical modeling. AEK, DD, RPM, and JM drafted other sections of the manuscript. All authors reviewed and agreed upon the final version of the manuscript. This assessment represents the views of the authors and not official positions of their employers.

Words: 4738

Abstract

Background

COVID-19 has rapidly emerged as a global public health threat with infections recorded in nearly every country. Responses to COVID-19 have varied in intensity and breadth, but generally have included domestic and international travel limitations, closure of non-essential businesses, and repurposing of health services. While these interventions have focused on testing, treatment, and mitigation of COVID-19, there have been reports of interruptions to diagnostic, prevention, and treatment services for other public health threats. We conducted a scoping review to characterize the impact of COVID-19 on HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.

Methods

A scoping literature review was completed using searches of PubMed and preprint servers (medRxiv/bioRxiv) from January 1st to October 31st, 2020, using Medical Subject Headings (MeSH) terms related to SARS-CoV-2 or COVID-19 and HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition. Empiric studies reporting original data collection and mathematical models were included, and available data synthesized by region. Studies were excluded if they were not written in English.

Results

A total of 1604 published papers and 205 preprints met inclusion criteria, including 8.2% (132/1604) of published studies and 10.2% (21/205) of preprints: 7.3% (68/931) on HIV, 7.1% (24/339) on tuberculosis, 11.6% (26/224) on malaria, 7.8% (13/166) on sexual and reproductive health, and 12.1% (16/132) on malnutrition. Thematic results were similar across competing health risks, with substantial indirect effects of the COVID-19 pandemic and response on diagnostic, prevention, and treatment services for HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.

Discussion

COVID-19 emerged in the context of existing public health threats that result in millions of deaths every year. Thus, effectively responding to COVID-19 while minimizing the negative impacts of COVID-19 necessitates innovation and integration of existing programs that are often siloed across health systems. Inequities have been a consistent driver of existing health threats; COVID-19 has worsened disparities, reinforcing the need for programs that address structural risks. Data reviewed here suggest that effective strengthening of health systems should include investment in public health with adequate funding to ensure continuity of care for emergent and existing public health threats.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is among the most significant public health emergencies of international concern over the last hundred years. As of December 2020, infections had been reported in most countries and the virus had resulted in substantial morbidity and mortality worldwide [1]. Responses to COVID-19 have varied in intensity, breadth, and duration, but in many countries have included domestic and international travel restrictions, stay-at-home orders and curfews, closure of non-essential businesses and schools, and repurposing of health services[2]. Although the goals of these interventions are to mitigate transmission of SARS-CoV-2 and ensure sufficient capacity for testing and treatment, such measures also have broader social, economic, and health impacts, including disruptions to routine public health programs and other clinical services[3-7]. Even when prevention or treatment services have remained uninterrupted, some people have been unwilling to seek care at healthcare facilities because of concerns about SARS-CoV-2 acquisition risk or due to the misconception that services are only available for patients with COVID-19[8].

Taken together, COVID-19 may have profound indirect and longer-term effects on broader health outcomes, including morbidity and mortality associated with other infectious and noncommunicable diseases. Moreover, there may be specific risks for increased indirect health effects of the COVID-19 pandemic in low- and middle-income countries secondary to suboptimal healthcare resources and infrastructure. Within all countries, existing socioeconomic inequities, driven in part by structural racism, are likely to shape who is most affected, both directly and indirectly, by COVID-19. Marginalized groups that already experienced inadequate access to prevention, diagnostic, and treatment services, as well as a higher prevalence of other health conditions, may be most profoundly impacted by further interruptions to prevention, diagnostic, and treatment services during the pandemic response.[9]

Understanding the indirect effects of COVID-19 on health services, overall health outcomes, and equity is critical for planning and adapting public health responses to emerging infections, which need to maximize control of an outbreak while minimizing setbacks in other areas of health. The purpose of this review was to characterize the impact of mitigation measures for the COVID-19 pandemic on health conditions that cause significant morbidity and mortality, including services and outcomes related to HIV infection, tuberculosis (TB), malaria, sexual and reproductive health (SRH), and malnutrition. To that end, we used a scoping rather than systematic review to summarize and disseminate research findings and reporting from a range of different data sources and study types [10]. The results of the scoping review are synthesized, including implications for global health investments and policies that can mitigate the indirect effects of COVID-19 and future public health emergencies of international concern.

Methods

We conducted a scoping review of published papers and preprints made available through October 31st, 2020. Search strategies (available in Appendix) were developed using MeSH and key terms were developed to focus on COVID-19 and its impact on one of the pre-specified key competing health risks: HIV, TB, malaria, SRH, and malnutrition. Abstracts and full-text articles were reviewed using Covidence[11],, an online systematic review management tool, and EndNote (version X8) [12].

Specifically, for SRH, this review focused on disruptions in selected essential services including contraceptives, abortion, pregnancy-related and newborn care. For published papers, searches were implemented in PubMed. For preprints, we conducted a search of the COVID-19 Living Evidence Database, which includes published papers and preprints from both medRxiv and bioRxiv and is updated daily (https://zika.ispm.unibe.ch/assets/data/pub/search_beta/).

Articles were included if the primary focus was the impact of COVID-19 on one of the five existing public health threats, and if they included empiric data on health or service outcomes or mathematical models. We excluded articles not written in English. Finally, commentaries were screened for key themes to support interpretation of the measured and modeled data.

Titles and abstracts were reviewed by a single reviewer and selected for inclusion in this review based on the above criteria. The reviewers of each of the sections were: HIV (AR), TB (CL), malaria (CL), SRH (JOTR), and malnutrition (JOTR). **Table 1** depicts the number of articles pulled, formally included based on the inclusion criteria, designated as commentaries, and excluded. Included articles were reviewed for data or mathematical models and themes in terms of epidemiology of the burden or associated mortality of the condition and changes to service delivery.

Results

Outcomes of the Scoping Review

The systematic search identified a total of 1604 published papers and 205 preprints. For articles related to the impact of COVID-19 mitigation strategies on the HIV edemic, 7.3% (68/931) were deemed relevant and included in this review, along with 7.1% (24/339) for TB, 11.6% (26/224) for malaria, 7.8% (13/166) for SRH, and 12.1% (16/132) for malnutrition. The number of selected papers that were screened and eligible are reported in **Table 1**.

COVID-19 Impact on HIV

Three main themes emerged from a review of the literature related to the potential impact on HIV. The majority of papers included in this review described a destabilization of HIV service delivery and the negative impact of COVID-19 mitigation efforts on HIV testing, access to care, and viral suppression.[13, 14] Across geographic contexts, including in Italy, Indonesia, Uganda, Kenya, and Australia, fewer people living with HIV reported being able to attend clinic visits and access antiretroviral therapy (ART), resulting in a decline in the number of people estimated to be virally suppressed [15-19]. For example, in a global survey of men who have sex with men (MSM), close to 20% (218/1105) reported being unable to access their HIV provider during the pandemic and half reported being unable to refill their HIV prescription remotely (820/1254).[18] In terms of HIV prevention, there has been a decline in the number of people being tested and diagnosed [15, 20-22] and the amount of pre-exposure prophylaxis (PrEP) [23, 24] and post-exposure prophylaxis dispensed[18, 25, 26], although these declines may be attributable in part to reductions in sexual activity. COVID-19 responses have resulted in interruptions to the supply chains for the distribution of both ART and PrEP, and stock-outs of medications, as one study from Indonesia described.[16]

Disparities have also been identified in who was affected by interruptions to HIV prevention and treatment services. Specifically, existing socioeconomic inequities, including reduced access to health insurance and unstable housing, have been associated with HIV service

interruptions.[14, 27] In addition, key populations—including MSM, female sex workers, people who use drugs, and transgender populations—that depend on services from community-based organizations because of stigma within the health sector may be particularly vulnerable to disruptions in outreach services caused by shelter-in-place mandates [28-30].

In some settings, there have been reported adaptations in the implementation of HIV service delivery to mitigate interruptions, including adoption of telemedicine [19, 31-36], home-based HIV testing and self-testing[37-39], home or mobile delivery of antiretrovirals[34, 35, 40], use of curbside pickup (i.e. pickup of supplies without stepping out of a vehicle) for condoms, lubricants, and medications[41], and designation of surrogates such as peers to motivate and support ongoing treatment.[19] Adaptation of clinical services has benefited from training of providers and approaches that have promoted trust and taken into consideration patients' needs and preferences.[32] Access to non-medical support, including cash transfers, reimbursement for the costs associated with accessing care,[19] and housing and food supplementation support, has been key to promoting ongoing engagement in care.[29, 39] However, medical support and telemedicine strategies alone are unlikely to fully mitigate the poorer HIV outcomes observed; one study from a safety-net HIV clinic in San Francisco found that the odds of viral non-suppression were 31% higher after a shelter-in place mandate compared to before the mandate, even with telemedicine services.[14] Notably, most studies describing adaptations have been in higher-income settings, though this may be a publication bias.

COVID-19 Impact on TB Care Cascade

Over the past several years, TB incidence and mortality have been steadily declining given improvements in diagnosis, treatment and prevention. The data available to date suggest that COVID-19 has resulted in disruptions that may challenge the WHO goal to end the TB pandemic by 2030.

Reductions in timely diagnosis and treatment of new TB cases have been caused by disruptions to access to healthcare services and availability of diagnostic capacity. Overwhelmed healthcare systems have often de-prioritized TB testing in laboratories and diverted these resources to COVID-19 testing [42]. In South Africa and Nigeria, for instance, GeneXpert machines and kits were prioritized for COVID-19 testing, leading to drop of more than 50% in the median number of daily GeneXpert TB tests[43, 44]. Social distancing measures implemented in many countries disrupted patients' access to care, which impeded diagnosis, initiation of appropriate treatment, and follow-up. In Bangladesh, Kenya, Nigeria and Pakistan, the ability of residents in lower-income communities—which have a higher risk of TB—to seek healthcare for TB services has been reduced during COVID-19-related restrictions[45]. Missed diagnoses increase opportunities for transmission, while worsened treatment outcomes increase the risk of TB-related morbidity and mortality.

There have been documented manifestations of interruptions to TB services [46, 47]. For instance, in 2020, there has been a substantial reduction in TB notifications in Sierra Leone, China, Nigeria, South Korea, India, the Philippines, Japan, and the U.S. compared to the same period in previous years [48-57]. Specifically, there was a decline of more than 50% in TB notifications in China in 2020 compared to 2015–2019.[58] Furthermore, in Nigeria and South Korea, there was a one-third decrease in the number active TB notifications in 2020 compared to prior years. As restrictive measures are lifted and COVID-19 rates decline, most of these settings are now reporting an increase in TB notification rates [48-57]. In addition,

reduced access to healthcare services and re-deployment of the TB workforce for the management of COVID-19 [59, 60] have created conditions for low adherence to treatment, which might also contribute to ongoing transmission and the emergence and spread of drug-resistant TB. During COVID-19-related restrictions in China, patient treatment completion and screening for drug-resistant TB among new and high-risk TB patients declined by approximately 20% [48].

At a broader level, COVID-19 prevention and mitigation measures have increased poverty and undernutrition, which are major risk factors for the acquisition and active conversion of TB. In India, an estimated 140 million people have lost their jobs during COVID-19 [61]. In Brazil, the regions hardest hit by Covid-19 largely overlap with the regions where higher TB rates are observed [62]. With increased poverty and undernutrition, TB cases may surge among these disadvantaged communities. Furthermore, as regular services continue to be disrupted, routine TB immunization programs have been affected, such as in Pakistan, where an over 40% decline in BCG vaccinations has been reported [63].

Multiple modelling studies have estimated that restriction-related disruptions and fragmentation of TB services could result in an increase in TB incidence and mortality[64, 65]. The Stop TB Partnership reported that without counter measures to maintain TB services, a 3-month COVID-19 lockdown followed by a 10-month recovery period could lead to an additional 6.3 million cases of TB by 2025 and an additional 1.4 million TB-related deaths in low- and middle-income countries[66]. Another modelling study estimated that over the next 5 years, these deaths could increase by up to 20%[67]. This emphasizes that the adverse effects of short-term disruptions will need to be addressed through “catch-up” TB case detection and treatment programs[68]. Critical efforts to mitigate impacts on TB control could include integration of TB and COVID-19 services for infection control, contact tracing, community-based care, surveillance and monitoring. Innovative ways to deliver medicines and collect specimens for follow-up TB testing at home, and combine screening for TB and COVID-19, have already been demonstrated in South Africa [40, 69]. The socioeconomic inequities driving both TB and COVID-19 highlight the need for all countries to invest in universal health coverage and ensure equitable access to services.

COVID-19 Impact on Malaria

Studies have collectively demonstrated challenges in maintaining malaria prevention and control efforts in the context of COVID-19. In a study of 106 countries, 73% of malaria programs reported disruption to service delivery, of which 19% reported high or very high levels of disruptions, potentially leading to increased morbidity and mortality.[70, 71] A resurgence of malaria due to COVID-19 may occur overall, and especially among vulnerable young children and pregnant women.[72-74] Of particular concern is the disruption of prevention efforts , including routine distribution of long-lasting insecticide-treated nets, seasonal malaria chemoprevention, and indoor residual spraying of insecticide.[72, 75] A modeling study suggested that the greatest impact on malaria burden could result from interruption of planned bed net campaigns, predicting 36% more deaths over 5 years in high-burdent settings than would have occurred without the COVID-19 disruptions.[67] Another mathematical model suggested that COVID-19-related disruptions to malaria chemoprevention efforts and distribution of insecticide-treated nets in sub-Saharan Africa may contribute to a doubling of malaria-related mortality in 2020.[76]

Malaria diagnoses during the COVID-19 outbreak have decreased, with a reduction in the notification rate as high as 62% in some settings.[77, 78] This reduction in diagnosis may be

due to several factors, including reductions in health-seeking behavior related to malaria, as individuals may be reluctant to visit health facilities due to COVID-19.[72, 77] Conversely, healthcare providers previously focused on delivering malaria care may have been reassigned to work on COVID-19, therefore limiting available malaria diagnostic services. COVID-19 and malaria have overlapping symptoms, including fever, difficulty breathing, headaches, and body pain, and there may be misdiagnosis of these infections in the context of limited laboratory testing.[79, 80] Furthermore, delays in reporting of malaria testing and confirmed cases have been observed, possibly due to disruptions in surveillance reporting structures.[77] Overall, undetected infections of malaria as a result of the focus on COVID-19 testing threatens control efforts for malaria.[81]

Chloroquine (CQ) and its derivative, hydroxychloroquine (HCQ), are established prophylactic and clinical treatments for malaria and widely used in endemic areas. Early in the COVID-19 pandemic, these antimalarials were considered as potential treatment of COVID-19, and the U.S. FDA issued a temporary emergency use authorization for the use of HCQ for treatment of COVID-19, which was then rescinded in June 2020.[82] Across settings, there was a documented increase in prescriptions of antimalarials, including an 80-fold increase in HCQ prescriptions in the U.S.[82] [83] Indiscriminate and widespread prophylactic and therapeutic use of CQ and CHQ for COVID-19 may complicate malaria prevention and control through several mechanisms. Alongside the increase in demand, shortages in the immediate supply may reduce their availability for use in malaria prevention and control, especially in low- and middle-income settings, which rely on international supply chains.[84, 85] Importantly, resistance to CQ and HCQ has previously emerged, and further indiscriminate use due to COVID-19 may drive Plasmodium resistance in malaria-endemic areas and threaten the control of malaria. [74, 81, 83, 86]

COVID-19 Impact on SRH Services

In terms of the impact on SRH, we focused on disruptions in selected essential services including contraceptives, abortion, pregnancy-related and newborn care.[87] Other SRH services and outcomes, such as screening, prevention and care related to sexually transmitted infections, sexual violence, and reproductive cancers, were beyond the scope of our review.

Early during the COVID-19 outbreak, Robertson et al.[88] estimated that a 10-52% drop in service coverage would result in 12,000-57,000 additional maternal deaths over a 6-month period in low- and middle-income countries. Similarly, Riley et al predicted that a 10% decline in SRH services would add 15.4 million unintended pregnancies, 3.3 million unsafe abortions, and 28,000 additional maternal deaths on a yearly basis [89]. While these estimates have yet to be measured empirically, data highlight SRH-related service disruptions, including 60 million fewer contraceptive users. These numbers are highest in Sub-Saharan Africa, Latin America, and the Caribbean, where the prevalence of provider-administered methods requiring face-to-face contact (such as injectable contraception) is the highest.[90, 91]

Social distancing measures have resulted in interruptions to commodity production, supply chain delays, and clinic closures, resulting in commodity shortages.[92] In India, Marie Stopes International reported serving 1.3 million fewer women with contraceptive and abortion services than expected.[93] To date, research studies have documented mixed results in terms of the impact of COVID-19 on service delivery outcomes [94-96]. Decreases in access to and use of contraceptives, antenatal care, safe abortion, and institutional delivery

have been documented across different health systems and income contexts, including Kenya,[97, 98] Ethiopia,[99] Turkey,[100] Italy,[101], UK,[102] and the US.[103-105] Notably, a recent large-scale prospective observational study in Nepal found a 52% decrease in institutional births coupled with increased neonatal mortality rates and poor intrapartum care during COVID-19-related restrictions [106].

Frontline maternal health workers have described changed care practices globally, such as relocation of human resources to the COVID-19 response, reduced face-to-face consultations, visitor bans (including for partners), and shorter post-delivery stays for mothers and infants [107-113]. Several adaptations have been introduced to mitigate the effects of these health systems challenges [114], including the Kenyan "Wheels for life initiative" to provide free transportation services to pregnant women during curfew hours,[97] "click and collect" access to contraceptives,[115] and increased transition to telemedicine [111, 114-117]. In particular, imposed abortion restrictions in a number of European countries[118] and the US[103, 104, 119] during COVID-19 have created an increased demand for medical abortion via telemedicine[118, 120-123], regardless of whether or not women are actually able to access such services [120, 123]. By contrast, countries such as Great Britain authorized telemedicine-based medical abortion services in order to ensure equity and continuity of care during COVID-19,[118] highlighting a demand for self-care services which will likely be continued in the future.[124]

COVID-19 Impact on Nutrition Services

The immediate effect of COVID-19 mitigation strategies on nutrition has been an increase in the number of individuals facing food insecurity in low, middle, and high-income countries[125, 126]. Food insecurity appears to be related to disruption of food supply chains due to limited movements of people and goods between countries, which in turn caused a disruption of food markets, increased food waste, and inflation of food prices.[127-129] This disruption of markets was exacerbated by the economic fallout associated with COVID-19, resulting in millions of people losing their source of income, particularly in low and middle income countries, where the majority of individuals work in the informal sector. Though food insecurity has affected individuals of all demographics, children and women of low socioeconomic status have been particularly affected by service interruptions due to COVID-19, and the effects may be long-lasting among these populations.

School closures have resulted in loss of access to healthy foods for millions of school-aged children and adolescents who relied on schools to access healthy meals[130-132]. In addition, among children less than five years of age, malnutrition has been projected to increase, resulting in substantial morbidity and mortality, especially among children from low- and middle-income countries[133]. For instance, a modelling study focusing on 118 low- and middle-income countries estimated that the disruptions in health services and increase food insecurity due to COVID-19 could result in a 14% increase in the prevalence of malnutrition, translating to 6.7 million more children under five experiencing severe malnutrition. The same study estimated that COVID-19 would be associated with more than 120,000 additional deaths among children under five because of increased malnutrition and other unmet child health needs. Maternal mortality is also expected to increase as a result of increased food insecurity and reduced access to maternal health programs [133, 134]. Specifically, a separate modelling study estimated an additional 12,200 to 56,700 maternal deaths could occur as a result of disruption in maternal health and nutrition programs [88].

Given the substantial negative effects on nutrition and the associated morbidity and mortality, several papers have lamented the lack of explicit nutrition programs in the COVID-19 response and called for integration of nutrition programs within COVID-19 mitigation strategies. Specific strategies to mitigate increased malnutrition could include population-level interventions targeting the most vulnerable[135]. In Nepal, for example, specific interventions to support COVID-19 efforts include continuation of vitamin A supplementation and provision of deworming tablets to children, programs supporting breastfeeding and other complementary foods, distribution of fortified foods to pregnant women, and ensuring the continuity of other existing maternal and child programs[134].

In addition to food insecurity, there has been an increase in unhealthy eating habits since the start of the pandemic. A cross-sectional study among over 1000 adult participants in Poland found a high prevalence of changes in eating habits, with 43% of participants reporting eating more frequently and 50% reporting more snacking. Furthermore, 30% of participants in the study reported weight gain and 19% reported weight loss since the initiation of COVID-19-related restrictions [136], while 15% of participants reported consuming more alcohol and 45% of smokers reported increased smoking frequency.

Discussion

In 2015, all United Nations Member States adopted the 2030 Agenda for Sustainable Development with a focus on 17 Sustainable Development Goals. To support health and wellbeing for all, the Sustainable Development Goals laid out ambitious plans for zero new HIV, malaria, and TB infections by 2030, and ambitious goals to address malnutrition and reproductive health. However, across high-, middle-, and lower-income countries, COVID-19 has been associated with reduced access to services, decreased diagnosis, and poorer health outcomes for HIV, tuberculosis, malaria, and sexual and reproductive health, and increases in malnutrition. The most affected populations appear to be communities already on the margins, including those with lower income, racial/ethnic minorities, and women, resulting in the amplification of existing health inequities. Increases in communicable diseases and malnutrition, worsened reproductive health outcomes, and widening inequities could collectively result in a reversal of global health gains in key indicators[137].

The indirect effects of the COVID-19 pandemic may force a reexamination of global health investments and policies. Specifically, it has been estimated that as much as 90% of countries have experienced declines in per capita income due to the COVID-19 pandemic and responses [138]. These decreases have prompted questions regarding the viability of the Sustainable Development Goals and whether they should reflect more achievable targets in the wake of programmatic disruptions due to COVID-19 [139]. In addition, as service disruptions and COVID-19-related restrictions are expected to disproportionately affect already-marginalized groups—such as adolescents, sexual and gender minority communities, people living with HIV, refugees and migrants, and people facing gender-based violence[89, 98, 140-142]—human-rights affirming, intersectional approaches for monitoring and addressing the indirect effects on programs are critical [18] [140]. Specific funding support to non-governmental organizations with strong connections to these communities may be able to overcome disruptions in health services during public health emergencies. Moreover, efforts to decriminalize marginalized populations should be prioritized to promote legal and economic opportunities, as well as access to health care. Finally, there have been calls for more resilient supply chains for medicine and food in low- and middle-income countries.

This requires supporting local market chains in those countries to avoid reliance on international food supply chains and strengthening their production and delivery of biofortified foods[128]

Despite differences of opinion in specific policy actions, there are a few areas where a broad consensus is emerging. Multilateral initiatives and commitments are more important than ever, and donors must redouble their efforts to invest in global health efforts rather than retrench to keep from losing decades of gains. COVID-19 has stressed the capacity of health systems because of vertical and siloed health infrastructure designed to respond to specific diseases. Integrated health systems can not only address a multiplicity of health issues, but also can support integrated surveillance, data systems, supply chain management, and delivery[143]. To inform these policy initiatives, there is a need for disease-specific approaches to shift towards studying communities of individuals and health systems.

The benefits of scientific discovery are not linear with respect to disease. For instance, scientific advances in HIV have benefited cancer and hepatitis research, and have served as a basis for COVID-19 vaccines.[144, 145] Similarly, these health conditions themselves are interrelated. For instance, TB is the leading cause of death for people living with HIV in sub-Saharan Africa.[146] However, disease-specific research has often failed to study and respond to the complexities of this reality. Before COVID-19, it would have been unusual to conduct research on the impact of a respiratory virus infection on domestic violence, depression, and job security among women living with HIV who were diabetic. However, given anecdotal and media reports of these relationships, research should evolve accordingly to better inform public health needs. Cross-disciplinary research initiatives can characterize the direct and indirect impacts of COVID-19, including implementation research on syndemic-related health outcomes, effects of legal policies (e.g., protections for marginalized populations), structural racism, and issues of food security and employment.[147-150] In addition, studies on optimizing resource allocation and supply chain management for therapeutics and vaccines are critical to avoid worsening of inequities during scale up.[151] To respond to these needs, the WHO convened a Global Research Forum early in February 2020 to accelerate research on the immediate priorities of COVID-19 mitigation and treatment, with secondary aims to build up global research platforms and drive equitable access to diagnostics and therapeutics.[117] Moreover, there was to be intentional assessment of how public health strategies may impact a multitude of factors across physical and mental health, as well as social infrastructure, economies, and politics.[152-154]

Mathematical models have played a significant role in COVID-19-related decision-making. As in previous outbreaks and pandemics, transmission dynamics and statistical modelling provided rapid estimates drawing on rapidly evolving information[155] [156]. Similar to the policy and research initiatives to date, infectious disease modelling has remained largely "vertical", or siloed by health threats, thus resembling and informing decision-making for vertical health services. As models are expected to continue to drive decision making, the next generation of pandemic preparedness models could integrate case projection for an emerging infectious disease and disease-specific health-care and public health needs with adaptive strategies for a resilient health care system. In projecting how many acute care hospital beds might be needed to care for patients with severe COVID-19, opportunities exist to integrate other conditions to manage the surges while also minimizing disruptions to health care services. For example, if estimates of the reduction in contact rates required to decrease SARS-CoV-2 spread were integrated, *a priori*, with local health system effects across health conditions and services, decision-makers could leverage quantified scenarios on differential

COVID-19 mitigation strategies alongside systems-level modelling to inform horizontal decision-making[157]. Separate from variability in underlying mortality, health system infrastructure varies significantly across regions, including health and human services per population or in hospital and intensive care beds per capita. Further integration of localized health infrastructure parameters with COVID-19 transmission models would also support localized decision making for optimal interventions [158-160].

There are several limitations of this scoping review. Given the breadth of information reviewed, including over 1800 peer-reviewed and preprint articles, we did not conduct a formal population-intervention-control-outcome systematic review. Moreover, there were several areas not covered in this review, including vaccine-preventable diseases[161], non-communicable diseases[162, 163], specific health effects among migrant communities[164], violence[165], and mental health[166]. Preliminary data suggest effects across all these areas, including reports of increased domestic violence, decreases in childhood vaccinations, and increases in mortality and morbidity because of acute mental health stressors and substance use. In addition, publication bias may have affected the estimates reported here. Because we did not complete a quantitative meta-analysis, we were unable to assess the magnitude of publication bias. Finally, there may be limited generalizability of the indirect effects of COVID-19 across regions given significant variability in the underlying causes of morbidity and mortality and varying health systems and health infrastructure.

Conclusions

The COVID-19 pandemic has exposed disparate risks and inequities by income, race and ethnicity, gender, and immigration status. The results of this scoping review demonstrate ways in which the COVID-19 pandemic and response have impacted other diseases and essential services, risking decades of progress in outcomes associated with HIV, TB, malaria, SRH, and malnutrition. Many settings have adapted, but optimizing population-level health in the context of public health emergencies of international concern necessitates innovation in research, mathematical modeling, policy, and programs. Moreover, a cross-disciplinary research agenda for pandemic preparedness and response modelling offers an opportunity to examine optimal decision making for ‘health care and public health ecosystems’ by joining forecasts and scenario-based projections from counterfactuals (‘what if’ experiments) for one disease with downstream impact of the ‘what if’ experiment on other health conditions. COVID-19 responses should also include a rights-based approach that helps ensure equitable access to prevention, diagnostic, and treatment services for both COVID-19 and competing health risks. The redesign and strengthening of health systems must include strengthening of public health systems, with adequate funding to ensure continuity of much needed programs addressing the needs of those most socially and economically marginalized.

Table 1. Number of papers pulled, included, marked as relevant commentaries, and excluded by competing health risk as part of the scoping review

PUBLISHED LITERATURE (PubMed)					
	HIV	**Malaria**	**Malnutrition**	**SRH**	**TB**
Pulled	827	189	125	162	301
Included	60	23	16	13	20
Commentaries	43	24	27	60	58
Excluded	724	165	82	89	223

PREPRINTS (COVID-19 Living Evidence database)					
	HIV	**Malaria**	**Malnutrition**	**SRH**	**TB**
Pulled	104	35	7	21	38
Included	8	3	0	6	4
Commentaries	0	0	0	0	1
Excluded	96	32	7	15	33

SRH=Sexual and Reproductive Health; TB=Tuberculosis

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases. 2020;20(5):533-4. doi: 10.1016/S1473-3099(20)30120-1.
2. Holland CE, Kouanda S, Lougue M, Pitche VP, Schwartz S, Anato S, et al. Using Population-Size Estimation and Cross-sectional Survey Methods to Evaluate HIV Service Coverage Among Key Populations in Burkina Faso and Togo. Public Health Rep. 2016;131(6):773-82. doi: 10.1177/0033354916677237. PubMed PMID: 28123223; PubMed Central PMCID: PMCPMC5230836.
3. Kazi DS, Wadhera RK, Shen C, Ho KKL, Patell R, Selim MH, et al. Decline in Emergent and Urgent Care during the COVID-19 Pandemic. medRxiv. 2020:2020.05.14.20096602. doi: 10.1101/2020.05.14.20096602.
4. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al. Impact of the COVID-19 Pandemic on Emergency Department Visits - United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699-704. Epub 2020/06/12. doi: 10.15585/mmwr.mm6923e1. PubMed PMID: 32525856; PubMed Central PMCID: PMCPMC7315789 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
5. Hungerford D, Cunliffe NA. Coronavirus disease (COVID-19) - impact on vaccine preventable diseases. Euro Surveill. 2020;25(18). Epub 2020/05/14. doi: 10.2807/1560-7917.ES.2020.25.18.2000756. PubMed PMID: 32400359; PubMed Central PMCID: PMCPMC7219030.
6. COVID-19 significantly impacts health services for noncommunicable diseases [Internet]. 2020
7. Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381-9. Epub 2020/07/18. doi: 10.1016/S0140-6736(20)31356-8. PubMed PMID: 32679111; PubMed Central PMCID: PMCPMC7429983.
8. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D, Schneider EC. The Impact of the COVID-19 Pandemic on Outpatient Care: Visits Return to Prepandemic Levels, but Not for All Providers and Patients. Commonwealth Fund, 2020.
9. CDC. Health Equity Considerations and Racial and Ethnic Minority Groups 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html.
10. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-73. Epub 2018/09/05. doi: 10.7326/M18-0850. PubMed PMID: 30178033.
11. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. 2020. Available from: www.covidence.org.
12. EndNote X8. Clarivate Analytics 2020. Available from: https://endnote.com/.
13. Ridgway JP, Schmitt J, Friedman E, Taylor M, Devlin S, McNulty M, et al. HIV Care Continuum and COVID-19 Outcomes Among People Living with HIV During the COVID-19 Pandemic, Chicago, IL. AIDS Behav. 2020;24(10):2770-2. doi: 10.1007/s10461-020-02905-2. PubMed PMID: 32382823.

14. Spinelli MA, Hickey MD, Glidden DV, Nguyen JQ, Oskarsson JJ, Havlir D, et al. Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19. Aids. 2020. doi: 10.1097/qad.0000000000002677. PubMed PMID: 32910069.
15. Quiros-Roldan E, Magro P, Carriero C, Chiesa A, El Hamad I, Tratta E, et al. Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy. AIDS Res Ther. 2020;17(1):59. doi: 10.1186/s12981-020-00314-y. PubMed PMID: 33012282.
16. Luis H, Fridayantara WD, Mahariski P, Wignall FS, Irwanto I, Gedela K. Evolving ART crisis for people living with HIV in Indonesia. Lancet HIV. 2020;7(6):e384-e5. doi: 10.1016/s2352-3018(20)30138-7. PubMed PMID: 32359421.
17. Linnemayr S, Jennings Mayo-Wilson L, Saya U, Wagner Z, MacCarthy S, Walukaga S, et al. HIV Care Experiences During the COVID-19 Pandemic: Mixed-Methods Telephone Interviews with Clinic-Enrolled HIV-Infected Adults in Uganda. AIDS Behav. 2020:1-12. doi: 10.1007/s10461-020-03032-8. PubMed PMID: 32918641.
18. Rao A, Rucinski K, Jarrett B, Ackerman B, Wallach S, Marcus J, et al. Potential interruptions in HIV prevention and treatment services for gay, bisexual, and other men who have sex with men associated with COVID-19. MedRxiv. 2020. doi: 10.1101/2020.08.19.20178285.
19. Nyoni T, Okumu M. COVID-19-Compliant Strategies for Supporting Treatment Adherence Among People Living with HIV in Sub-Saharan Africa. AIDS Behav. 2020;24(9):2473-6. doi: 10.1007/s10461-020-02888-0. PubMed PMID: 32333204.
20. Ponticiello M, Mwanga-Amumpaire J, Tushemereirwe P, Nuwagaba G, King R, Sundararajan R. "Everything is a Mess": How COVID-19 is Impacting Engagement with HIV Testing Services in Rural Southwestern Uganda. AIDS Behav. 2020;24(11):3006-9. doi: 10.1007/s10461-020-02935-w. PubMed PMID: 32451939.
21. Darcis G, Vaira D, Moutschen M. Impact of coronavirus pandemic and containment measures on HIV diagnosis. Epidemiol Infect. 2020;148:e185. doi: 10.1017/s0950268820001867. PubMed PMID: 32829742.
22. Ejima K, Koizumi Y, Yamamoto N, Rosenberg M, Ludema C, Bento AI, et al. HIV testing by public health centers and municipalities, and new HIV cases during the COVID-19 pandemic in Japan. MedRxiv. 2020. doi: 10.1101/2020.10.16.20213959.
23. Hammoud MA, Grulich A, Holt M, Maher L, Murphy D, Jin F, et al. Substantial decline in use of HIV pre-exposure prophylaxis (PrEP) following introduction of COVID-19 physical distancing restrictions in Australia: Results from a prospective observational study of gay and bisexual men. J Acquir Immune Defic Syndr. 2020. doi: 10.1097/qai.0000000000002514. PubMed PMID: 33027151.
24. Chow EPF, Hocking JS, Ong JJ, Schmidt T, Buchanan A, Rodriguez E, et al. Changing the Use of HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men During the COVID-19 Pandemic in Melbourne, Australia. Open Forum Infect Dis. 2020;7(7):ofaa275. doi: 10.1093/ofid/ofaa275. PubMed PMID: 32704518.
25. Sánchez-Rubio J, Vélez-Díaz-Pallarés M, Rodríguez González C, Sanmartin Fenollera P, García Yubero C, Fernández-Pacheco García-Valdecasas M. HIV postexposure prophylaxis during the COVID-19 pandemic: experience from Madrid. Sex Transm Infect. 2020. doi: 10.1136/sextrans-2020-054680. PubMed PMID: 32680842.
26. Chow EPF, Hocking JS, Ong JJ, Phillips TR, Fairley CK. Postexposure prophylaxis during COVID-19 lockdown in Melbourne, Australia. Lancet HIV. 2020;7(8):e528-e9. doi: 10.1016/s2352-3018(20)30204-6. PubMed PMID: 32687796.

27. Qiao S, Li Z, Weissman S, Li X, Olatosi B, Davis C, et al. Disparity in HIV Service Interruption in the Outbreak of COVID-19 in South Carolina. AIDS Behav. 2020:1-9. doi: 10.1007/s10461-020-03013-x. PubMed PMID: 32856176.
28. Gichuna S, Hassan R, Sanders T, Campbell R, Mutonyi M, Mwangi P. Access to Healthcare in a time of COVID-19: Sex Workers in Crisis in Nairobi, Kenya. Glob Public Health. 2020;15(10):1430-42. doi: 10.1080/17441692.2020.1810298. PubMed PMID: 32816628.
29. Santos GM, Ackerman B, Rao A, Wallach S, Ayala G, Lamontage E, et al. Economic, Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men. AIDS Behav. 2020:1-11. doi: 10.1007/s10461-020-02969-0. PubMed PMID: 32654021.
30. Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the Impact of COVID-19 on Men Who Have Sex with Men Across the United States in April, 2020. AIDS Behav. 2020;24(7):2024-32. doi: 10.1007/s10461-020-02894-2. PubMed PMID: 32350773.
31. Rogers BG, Arnold T, Schierberl Scherr A, Strong SH, Holcomb R, Daley Ndoye C, et al. Adapting Substance Use Treatment for HIV Affected Communities During COVID-19: Comparisons Between a Sexually Transmitted Infections (STI) Clinic and a Local Community Based Organization. AIDS Behav. 2020;24(11):2999-3002. doi: 10.1007/s10461-020-02933-y. PubMed PMID: 32462344.
32. Mgbako O, Miller EH, Santoro AF, Remien RH, Shalev N, Olender S, et al. COVID-19, Telemedicine, and Patient Empowerment in HIV Care and Research. AIDS Behav. 2020;24(7):1990-3. doi: 10.1007/s10461-020-02926-x. PubMed PMID: 32440970.
33. Hoagland B, Torres TS, Bezerra DRB, Geraldo K, Pimenta C, Veloso VG, et al. Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV prevention service in Rio de Janeiro-Brazil. Braz J Infect Dis. 2020;24(4):360-4. doi: 10.1016/j.bjid.2020.05.004. PubMed PMID: 32504552.
34. Armstrong WS, Agwu AL, Barrette EP, Ignacio RB, Chang JJ, Colasanti JA, et al. Innovations in HIV care delivery during the COVID-19 pandemic: Policies to strengthen the Ending the Epidemic Initiative - A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa1532. PubMed PMID: 33035296.
35. Giuliani M, Donà MG, La Malfa A, Pasquantonio MS, Pimpinelli F, Cristaudo A, et al. Ensuring retention in care for people living with HIV during the COVID-19 pandemic in Rome, Italy. Sex Transm Infect. 2020. doi: 10.1136/sextrans-2020-054650. PubMed PMID: 33046581.
36. Dourado I, Magno L, Soares F, Massa P, Nunn A, Dalal S, et al. Adapting to the COVID-19 Pandemic: Continuing HIV Prevention Services for Adolescents Through Telemonitoring, Brazil. AIDS Behav. 2020;24(7):1994-9. doi: 10.1007/s10461-020-02927-w. PubMed PMID: 32440973.
37. Menza TW, Garai J, Ferrer J, Hecht J. Rapid Uptake of Home-Based HIV Self-testing During Social Distancing for SARS-CoV2 Infection in Oregon. AIDS Behav. 2020:1-4. doi: 10.1007/s10461-020-02959-2. PubMed PMID: 32594272.
38. Mhango M, Chitungo I, Dzinamarira T. COVID-19 Lockdowns: Impact on Facility-Based HIV Testing and the Case for the Scaling Up of Home-Based Testing Services in Sub-Saharan Africa. AIDS Behav. 2020;24(11):3014-6. doi: 10.1007/s10461-020-02939-6. PubMed PMID: 32488551.

39. Odinga MM, Kuria S, Muindi O, Mwakazi P, Njraini M, Melon M, et al. HIV testing amid COVID-19: community efforts to reach men who have sex with men in three Kenyan counties. Gates Open Res. 2020;4:117. doi: 10.12688/gatesopenres.13152.1. PubMed PMID: 32954217.
40. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus disease 2019, Cape Town, South Africa: Short report. Afr J Prim Health Care Fam Med. 2020;12(1):e1-e4. doi: 10.4102/phcfm.v12i1.2449. PubMed PMID: 32501022.
41. Kay ES, Musgrove K. From HIV to Coronavirus: AIDS Service Organizations Adaptative Responses to COVID-19, Birmingham, Alabama. AIDS Behav. 2020;24(9):2461-2. doi: 10.1007/s10461-020-02879-1. PubMed PMID: 32333206.
42. Mohammed H, Oljira L, Roba KT, Yimer G, Fekadu A, Manyazewal T. Containment of COVID-19 in Ethiopia and implications for tuberculosis care and research. Infectious Diseases of Poverty. 2020;9(1):131. doi: 10.1186/s40249-020-00753-9.
43. Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care. Science. 2020;369(6502):366-8. Epub 2020/07/25. doi: 10.1126/science.abd1072. PubMed PMID: 32703860.
44. Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Annals of Clinical Microbiology and Antimicrobials. 2020;19(1):21. doi: 10.1186/s12941-020-00363-1.
45. Ahmed SAKS, Ajisola M, Azeem K, Bakibinga P, Chen Y-F, Choudhury NN, et al. Impact of the societal response to COVID-19 on access to healthcare for non-COVID-19 health issues in slum communities of Bangladesh, Kenya, Nigeria and Pakistan: results of pre-COVID and COVID-19 lockdown stakeholder engagements. BMJ Global Health. 2020;5(8):e003042. doi: 10.1136/bmjgh-2020-003042.
46. Migliori GB, Thong PM, Akkerman O, Alffenaar J-W, Álvarez-Navascués F, Assao-Neino MM, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. Emerging Infectious Disease journal. 2020;26(11):2709. doi: 10.3201/eid2611.203163.
47. Shen X, Sha W, Yang C, Pan Q, Cohen T, Chen S, et al. Continuity of services for patients with tuberculosis in China in the COVID-19 era. medRxiv. 2020:2020.07.16.20150292. doi: 10.1101/2020.07.16.20150292.
48. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Tuberculosis Control in Jiangsu Province, China. Clinical Infectious Diseases. 2020. doi: 10.1093/cid/ciaa1289.
49. Kwak N, Hwang S-S, Yim J-J. Effect of COVID-19 on Tuberculosis Notification, South Korea. Emerging Infectious Disease journal. 2020;26(10):2506. doi: 10.3201/eid2610.202782.
50. Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria. Int J Tuberc Lung Dis. 2020;24(9):981-2. Epub 2020/11/07. doi: 10.5588/ijtld.20.0418. PubMed PMID: 33156771.
51. Louie JK, Reid M, Stella J, Agraz-Lara R, Graves S, Chen L, et al. A decrease in tuberculosis evaluations and diagnoses during the COVID-19 pandemic. Int J Tuberc Lung Dis. 2020;24(8):860-2. Epub 2020/09/12. doi: 10.5588/ijtld.20.0364. PubMed PMID: 32912395.
52. Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care in Sierra Leone. Pulmonology. 2020. doi: https://doi.org/10.1016/j.pulmoe.2020.05.013.

53. Chen H, Zhang K. Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China. European Respiratory Journal. 2020;56(3):2002710. doi: 10.1183/13993003.02710-2020.
54. Chiang C-Y, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, et al. The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region. European Respiratory Journal. 2020;56(4):2003054. doi: 10.1183/13993003.03054-2020.
55. Datta B, Jaiswal A, Goyal P, Prakash A, Tripathy JP, Trehan N. The untimely demise of the TB Free block model in the wake of coronavirus disease 2019 in India. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2020;114(11):789-91. doi: 10.1093/trstmh/traa067.
56. Komiya K, Yamasue M, Takahashi O, Hiramatsu K, Kadota JI, Kato S. The COVID-19 pandemic and the true incidence of Tuberculosis in Japan. J Infect. 2020;81(3):e24-e5. Epub 2020/07/11. doi: 10.1016/j.jinf.2020.07.004. PubMed PMID: 32650109; PubMed Central PMCID: PMCPMC7338857.
57. Lai CC, Yu WL. The COVID-19 pandemic and tuberculosis in Taiwan. J Infect. 2020;81(2):e159-e61. Epub 2020/06/14. doi: 10.1016/j.jinf.2020.06.014. PubMed PMID: 32534000; PubMed Central PMCID: PMCPMC7286835.
58. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral Impact of the Covid-19 Pandemic on Tuberculosis Control in Jiangsu Province, China. Clin Infect Dis. 2020. Epub 2020/08/29. doi: 10.1093/cid/ciaa1289. PubMed PMID: 32857838; PubMed Central PMCID: PMCPMC7499510.
59. Khan MS, Rego S, Rajal JB, Bond V, Fatima RK, Isani AK, et al. Mitigating the impact of COVID-19 on tuberculosis and HIV services: a cross-sectional survey of 669 health professionals in 64 low and middle-income countries. medRxiv. 2020:2020.10.08.20207969. doi: 10.1101/2020.10.08.20207969.
60. Cronin AM, Railey S, Fortune D, Wegener DH, Davis JB. Notes from the Field: Effects of the COVID-19 Response on Tuberculosis Prevention and Control Efforts - United States, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):971-2. Epub 2020/07/24. doi: 10.15585/mmwr.mm6929a4. PubMed PMID: 32701944; PubMed Central PMCID: PMCPMC7377818 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
61. Husain AA, Monaghan TM, Kashyap RS. Impact of COVID-19 pandemic on tuberculosis care in India. Clin Microbiol Infect. 2020. Epub 2020/08/22. doi: 10.1016/j.cmi.2020.08.014. PubMed PMID: 32822881; PubMed Central PMCID: PMCPMC7434422.
62. Ribeiro VST, Telles JP, Tuon FF. Concerns about COVID-19 and tuberculosis in Brazil: Social and public health impacts. Enfermedades Infecciosas y Microbiología Clínica. 2020. doi: https://doi.org/10.1016/j.eimc.2020.08.013.
63. Chandir S, Siddiqi DA, Mehmood M, Setayesh H, Siddique M, Mirza A, et al. Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An analysis of provincial electronic immunization registry data. Vaccine. 2020;38(45):7146-55. doi: https://doi.org/10.1016/j.vaccine.2020.08.019.
64. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv. 2020:2020.04.28.20079582. doi: 10.1101/2020.04.28.20079582.
65. McQuaid CF, McCreesh N, Read JM, Sumner T, Houben RMGJ, White RG, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. European Respiratory Journal. 2020;56(2):2001718. doi: 10.1183/13993003.01718-2020.

66. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine. 2020;28:100603. Epub 2020/11/03. doi: 10.1016/j.eclinm.2020.100603. PubMed PMID: 33134905; PubMed Central PMCID: PMCPMC7584493.
67. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020;8(9):e1132-e41. doi: 10.1016/s2214-109x(20)30288-6. PubMed PMID: 32673577.
68. Cox V, Wilkinson L, Grimsrud A, Hughes J, Reuter A, Conradie F, et al. Critical changes to services for TB patients during the COVID-19 pandemic. The International Journal of Tuberculosis and Lung Disease. 2020;24(5):542-4. doi: 10.5588/ijtld.20.0205.
69. Malik AA, Safdar N, Chandir S, Khan U, Khowaja S, Riaz N, et al. Tuberculosis control and care in the era of COVID-19. Health Policy and Planning. 2020;35(8):1130-2. doi: 10.1093/heapol/czaa109.
70. Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting the Impact of COVID-19 and the Potential Impact of the Public Health Response on Disease Burden in Uganda. Am J Trop Med Hyg. 2020;103(3):1191-7. doi: 10.4269/ajtmh.20-0546. PubMed PMID: 32705975.
71. Guerra CA, Tresor Donfack O, Motobe Vaz L, Mba Nlang JA, Nze Nchama LO, Mba Eyono JN, et al. Malaria vector control in sub-Saharan Africa in the time of COVID-19: no room for complacency. BMJ Glob Health. 2020;5(9). doi: 10.1136/bmjgh-2020-003880. PubMed PMID: 32938611.
72. Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, et al. Identifying and combating the impacts of COVID-19 on malaria. BMC Med. 2020;18(1):239. doi: 10.1186/s12916-020-01710-x. PubMed PMID: 32727467.
73. Mejia R, Hotez P, Bottazzi ME. Global COVID-19 Efforts as the Platform to Achieving the Sustainable Development Goals. Curr Trop Med Rep. 2020:1-5. doi: 10.1007/s40475-020-00209-y. PubMed PMID: 32844081.
74. Robinson EF, Moulder JK, Zerden ML, Miller AM, Zite NB. Preserving and advocating for essential care for women during the coronavirus disease 2019 pandemic. Am J Obstet Gynecol. 2020;223(2):219-20.e1. doi: 10.1016/j.ajog.2020.05.022. PubMed PMID: 32405073.
75. Nghochuzie NN, Olwal CO, Udoakang AJ, Amenga-Etego LN, Amambua-Ngwa A. Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak? Front Microbiol. 2020;11:1476. doi: 10.3389/fmicb.2020.01476. PubMed PMID: 32625198.
76. Weiss DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, Arambepola R, Battle KE, et al. Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis. Lancet Infect Dis. 2020. doi: 10.1016/s1473-3099(20)30700-3. PubMed PMID: 32971006.
77. Torres K, Alava F, Soto-Calle V, Llanos-Cuentas A, Rodriguez H, Llacsahuanga L, et al. Malaria Situation in the Peruvian Amazon during the COVID-19 Pandemic. Am J Trop Med Hyg. 2020. doi: 10.4269/ajtmh.20-0889. PubMed PMID: 32885776.
78. Buonsenso D, Cinicola B, Kallon MN, Iodice F. Child Healthcare and Immunizations in Sub-Saharan Africa During the COVID-19 Pandemic. Front Pediatr. 2020;8:517. doi: 10.3389/fped.2020.00517. PubMed PMID: 32850565.

79. Beshir KB, Grignard L, Hajissa K, Mohammed A, Nurhussein AM, Ishengoma DS, et al. Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-19 Pandemic? Am J Trop Med Hyg. 2020;103(2):558-60. doi: 10.4269/ajtmh.20-0467. PubMed PMID: 32553046.
80. Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries. Int J Infect Dis. 2020;94:151-3. doi: 10.1016/j.ijid.2020.04.007. PubMed PMID: 32344326.
81. Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K. The impact of COVID-19 pandemic on malaria elimination. Parasite Epidemiol Control. 2020:e00187. doi: 10.1016/j.parepi.2020.e00187. PubMed PMID: 33102823.
82. Bull-Otterson L, Gray EB, Budnitz DS, Strosnider HM, Schieber LZ, Courtney J, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(35):1210-5. doi: 10.15585/mmwr.mm6935a4. PubMed PMID: 32881845.
83. Mvumbi DM. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings. Med Hypotheses. 2020;143:109912. doi: 10.1016/j.mehy.2020.109912. PubMed PMID: 32498009.
84. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med Hyg. 2020;102(6):1184-8. doi: 10.4269/ajtmh.20-0290. PubMed PMID: 32323646.
85. Cox S. To dispense or not to dispense: Lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic. Dev World Bioeth. 2020. doi: 10.1111/dewb.12284. PubMed PMID: 32844516.
86. Rodriguez-Valero N, Vera I, Torralvo MR, De Alba T, Ferrer E, Camprubi D, et al. Malaria prophylaxis approach during COVID-19 pandemic. Travel Med Infect Dis. 2020:101716. doi: 10.1016/j.tmaid.2020.101716. PubMed PMID: 32360423.
87. Starrs AM, Ezeh AC, Barker G, Basu A, Bertrand JT, Blum R, et al. Accelerate progress-sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission. Lancet. 2018;391(10140):2642-92. Epub 2018/05/14. doi: 10.1016/S0140-6736(18)30293-9. PubMed PMID: 29753597.
88. Roberton T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020;8(7):e901-e8. PubMed PMID: 32405459.
89. Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the Potential Impact of the COVID-19 Pandemic on Sexual and Reproductive Health In Low- and Middle-Income Countries. Int Perspect Sex Reprod Health. 2020;46:73-6. Epub 2020/04/29. doi: 10.1363/46e9020. PubMed PMID: 32343244.
90. Dasgupta A, Kantorova V, Ueffing P. The impact of the COVID-19 crisis on meeting needs for family planning: a global scenario by contraceptive methods used. Gates Open Res. 2020;4:102. Epub 2020/12/19. doi: 10.12688/gatesopenres.13148.2. PubMed PMID: 33330836; PubMed Central PMCID: PMCPMC7720714.
91. Weinberger M, Hayes B, White J, Skibiak J. Doing Things Differently: What It Would Take to Ensure Continued Access to Contraception During COVID-19. Glob Health Sci Pract.

2020;8(2):169-75. Epub 2020/06/21. doi: 10.9745/GHSP-D-20-00171. PubMed PMID: 32561528; PubMed Central PMCID: PMCPMC7326519.
92. Purdy C. How will COVID-19 affect global access to contraceptives—and what can we do about it? Devex. 2020.
93. Marie Stopes International (MSI). Resilience, adaptation and action. MSI's response to COVID-19. MSI, August, 2020.
94. Siedner MJ, Kraemer JD, Meyer MJ, Harling G, Mngomezulu T, Gabela P, et al. Access to primary healthcare during lockdown measures for COVID-19 in rural South Africa: an interrupted time series analysis. BMJ Open. 2020;10(10):e043763. doi: 10.1136/bmjopen-2020-043763. PubMed PMID: 33020109.
95. Coombe J, Kong F, Bittleston H, Williams H, Tomnay J, Vaisey A, et al. The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey. medRxiv. 2020:2020.08.10.20172163. doi: 10.1101/2020.08.10.20172163.
96. Shikuku DN, Nyaoke I, Gichuru S, Maina O, Eyinda M, Godia P, et al. Early indirect impact of COVID-19 pandemic on utilization and outcomes of reproductive, maternal, newborn, child and adolescent health services in Kenya. medRxiv. 2020:2020.09.09.20191247. doi: 10.1101/2020.09.09.20191247.
97. Wangamati CK, Sundby J. The ramifications of COVID-19 on maternal health in Kenya. Sex Reprod Health Matters. 2020;28(1):1804716. doi: 10.1080/26410397.2020.1804716. PubMed PMID: 32896231.
98. Skuster P, Khanal RC, Nyamato E. Relics of imperialism: US foreign policy on abortion in the COVID era. Sex Reprod Health Matters. 2020;28(3):1824319. doi: 10.1080/26410397.2020.1824319. PubMed PMID: 33048026.
99. Abdela SG, Berhanu AB, Ferede LM, van Griensven J. Essential Healthcare Services in the Face of COVID-19 Prevention: Experiences from a Referral Hospital in Ethiopia. Am J Trop Med Hyg. 2020;103(3):1198-200. doi: 10.4269/ajtmh.20-0464. PubMed PMID: 32762799.
100. Yuksel B, Ozgor F. Effect of the COVID-19 pandemic on female sexual behavior. Int J Gynaecol Obstet. 2020;150(1):98-102. doi: 10.1002/ijgo.13193. PubMed PMID: 32392400.
101. Caruso S, Rapisarda AMC, Minona P. Sexual activity and contraceptive use during social distancing and self-isolation in the COVID-19 pandemic. Eur J Contracept Reprod Health Care. 2020:1-4. doi: 10.1080/13625187.2020.1830965. PubMed PMID: 33044107.
102. Thomson-Glover R, Hamlett H, Weston D, Ashby J. Coronavirus (COVID-19) and young people's sexual health. Sex Transm Infect. 2020;96(7):473-4. doi: 10.1136/sextrans-2020-054699. PubMed PMID: 33077611.
103. Ahmed A. How the COVID-19 response is altering the legal and regulatory landscape on abortion. J Law Biosci. 2020;7(1):lsaa012. doi: 10.1093/jlb/lsaa012. PubMed PMID: 32728459.
104. Fulcher IR, Neill S, Bharadwa S, Goldberg AB, Janiak E. State and federal abortion restrictions increase risk of COVID-19 exposure by mandating unnecessary clinic visits. Contraception. 2020. doi: 10.1016/j.contraception.2020.08.017. PubMed PMID: 32905791.
105. Gildner TE, Thayer ZM. Birth plan alterations among American women in response to COVID-19. Health Expect. 2020;23(4):969-71. doi: 10.1111/hex.13077. PubMed PMID: 32449262.
106. Ashish K, Gurung R, Kinney MV, Sunny AK, Moinuddin M, Basnet O, et al. Effect of the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality outcomes in Nepal: a prospective observational study. The Lancet Global health.

2020;8(10):e1273-e81. Epub 2020/08/10. doi: 10.1016/S2214-109X(20)30345-4. PubMed PMID: 32791117.
107. Coxon K, Turienzo CF, Kweekel L, Goodarzi B, Brigante L, Simon A, et al. The impact of the coronavirus (COVID-19) pandemic on maternity care in Europe. Midwifery. 2020;88:102779. doi: 10.1016/j.midw.2020.102779. PubMed PMID: 32600862.
108. Davis-Floyd R, Gutschow K, Schwartz DA. Pregnancy, Birth and the COVID-19 Pandemic in the United States. Med Anthropol. 2020;39(5):413-27. doi: 10.1080/01459740.2020.1761804. PubMed PMID: 32406755.
109. Graham WJ, Afolabi B, Benova L, Campbell OMR, Filippi V, Nakimuli A, et al. Protecting hard-won gains for mothers and newborns in low-income and middle-income countries in the face of COVID-19: call for a service safety net. BMJ Glob Health. 2020;5(6). doi: 10.1136/bmjgh-2020-002754. PubMed PMID: 32499220.
110. Pallangyo E, Nakate MG, Maina R, Fleming V. The impact of covid-19 on midwives' practice in Kenya, Uganda and Tanzania: A reflective account. Midwifery. 2020;89:102775. doi: 10.1016/j.midw.2020.102775. PubMed PMID: 32526597.
111. Rimmer MP, Al Wattar BH. Provision of obstetrics and gynaecology services during the COVID-19 pandemic: a survey of junior doctors in the UK National Health Service. Bjog. 2020;127(9):1123-8. doi: 10.1111/1471-0528.16313. PubMed PMID: 32460422.
112. Rochelson B, Nimaroff M, Combs A, Schwartz B, Meirowitz N, Vohra N, et al. The care of pregnant women during the COVID-19 pandemic - response of a large health system in metropolitan New York. J Perinat Med. 2020;48(5):453-61. doi: 10.1515/jpm-2020-0175. PubMed PMID: 32432568.
113. Semaan A, Audet C, Huysmans E, Afolabi B, Assarag B, Banke-Thomas A, et al. Voices from the frontline: findings from a thematic analysis of a rapid online global survey of maternal and newborn health professionals facing the COVID-19 pandemic. BMJ Global Health. 2020;5(6):e002967. doi: 10.1136/bmjgh-2020-002967.
114. Benova L, Sarkar ND, Fasehun LO, Semaan A, Affun-Adegbulu C. A call to action: Documenting and sharing solutions and adaptations in sexual, reproductive, maternal and newborn health care provision during the COVID-19 pandemic. Sex Reprod Health Matters. 2020:1-5. doi: 10.1080/26410397.2020.1838054. PubMed PMID: 33073726.
115. Bateson DJ, Lohr PA, Norman WV, Moreau C, Gemzell-Danielsson K, Blumenthal PD, et al. The impact of COVID-19 on contraception and abortion care policy and practice: experiences from selected countries. BMJ Sex Reprod Health. 2020;46(4):241-3. doi: 10.1136/bmjsrh-2020-200709. PubMed PMID: 32788180.
116. Cohen MA, Powell AM, Coleman JS, Keller JM, Livingston A, Anderson JR. Special ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-19) and implications for future practice. Am J Obstet Gynecol. 2020;223(3):372-8. doi: 10.1016/j.ajog.2020.06.006. PubMed PMID: 32522513.
117. Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares-Júnior JM, et al. Contraception and reproductive planning during the COVID-19 pandemic. Expert Rev Clin Pharmacol. 2020;13(6):615-22. doi: 10.1080/17512433.2020.1782738. PubMed PMID: 32538185.
118. Moreau C, Shankar M, Glasier A, Cameron S, Gemzell-Danielsson K. Abortion regulation in Europe in the era of COVID-19: a spectrum of policy responses. BMJ Sex Reprod Health. 2020. doi: 10.1136/bmjsrh-2020-200724. PubMed PMID: 33093040.

119. Jones RK, Lindberg L, Witwer E. COVID-19 Abortion Bans and Their Implications for Public Health. Perspect Sex Reprod Health. 2020. doi: 10.1363/psrh.12139. PubMed PMID: 32408393.
120. Aiken ARA, Starling JE, Gomperts R, Tec M, Scott JG, Aiken CE. Demand for Self-Managed Online Telemedicine Abortion in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2020;136(4):835-7. doi: 10.1097/aog.0000000000004081. PubMed PMID: 32701762.
121. Caruana-Finkel L. Abortion in the time of COVID-19: perspectives from Malta. Sex Reprod Health Matters. 2020;28(1):1780679. doi: 10.1080/26410397.2020.1780679. PubMed PMID: 32516072.
122. Cioffi A, Cioffi F, Rinaldi R. COVID-19 and abortion: The importance of guaranteeing a fundamental right. Sex Reprod Healthc. 2020;25:100538. doi: 10.1016/j.srhc.2020.100538. PubMed PMID: 32534228.
123. Aiken ARA, Starling JE, Gomperts R, Scott JG, Aiken C. Demand for Self-Managed Online Telemedicine Abortion in Eight European Countries During the COVID-19 Pandemic: A Regression Discontinuity Analysis. medRxiv. 2020:2020.09.15.20195222. doi: 10.1101/2020.09.15.20195222.
124. Erlank CP, Lord J, Church K. Early medical abortion using telemedicine – acceptability to patients. medRxiv. 2020:2020.11.11.20229377. doi: 10.1101/2020.11.11.20229377.
125. Nagata JM, Seligman HK, Weiser SD. Perspective: The Convergence of Coronavirus Disease 2019 (COVID-19) and Food Insecurity in the United States. Adv Nutr. 2020. doi: 10.1093/advances/nmaa126. PubMed PMID: 32970098.
126. Kalu B. COVID-19 in Nigeria: a disease of hunger. Lancet Respir Med. 2020;8(6):556-7. doi: 10.1016/s2213-2600(20)30220-4. PubMed PMID: 32359414.
127. Brizi A, Biraglia A. "Do I have enough food?" How need for cognitive closure and gender impact stockpiling and food waste during the COVID-19 pandemic: A cross-national study in India and the United States of America. Pers Individ Dif. 2021;168:110396. doi: 10.1016/j.paid.2020.110396. PubMed PMID: 32982000.
128. Heck S, Campos H, Barker I, Okello JJ, Baral A, Boy E, et al. Resilient agri-food systems for nutrition amidst COVID-19: evidence and lessons from food-based approaches to overcome micronutrient deficiency and rebuild livelihoods after crises. Food Secur. 2020;12(4):823-30. doi: 10.1007/s12571-020-01067-2. PubMed PMID: 32839664.
129. Kabir M, Saqib MAN, Zaid M, Ahmed H, Afzal MS. COVID-19, economic impact and child mortality: A global concern. Clin Nutr. 2020;39(7):2322-3. doi: 10.1016/j.clnu.2020.05.027. PubMed PMID: 32499056.
130. Lobascio F, Caccialanza R, Monaco T, Cereda E, Secondino S, Masi S, et al. Providing nutritional care to cancer patients during the COVID-19 pandemic: an Italian perspective. Support Care Cancer. 2020;28(9):3987-9. doi: 10.1007/s00520-020-05557-z. PubMed PMID: 32495030.
131. Masonbrink AR, Hurley E. Advocating for Children During the COVID-19 School Closures. Pediatrics. 2020;146(3). doi: 10.1542/peds.2020-1440. PubMed PMID: 32554517.
132. Mayurasakorn K, Pinsawas B, Mongkolsucharitkul P, Sranacharoenpong K, Damapong SN. School closure, COVID-19 and lunch programme: Unprecedented undernutrition crisis in low-middle income countries. J Paediatr Child Health. 2020;56(7):1013-7. doi: 10.1111/jpc.15018. PubMed PMID: 32619327.

133. Akseer N, Kandru G, Keats EC, Bhutta ZA. COVID-19 pandemic and mitigation strategies: implications for maternal and child health and nutrition. Am J Clin Nutr. 2020;112(2):251-6. doi: 10.1093/ajcn/nqaa171. PubMed PMID: 32559276.
134. Panthi B, Khanal P, Dahal M, Maharjan S, Nepal S. An urgent call to address the nutritional status of women and children in Nepal during COVID-19 crises. Int J Equity Health. 2020;19(1):87. doi: 10.1186/s12939-020-01210-7. PubMed PMID: 32503613.
135. Hakeem R, Sheikh MA. Beyond transmission: Dire need for integration of nutrition interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan. Pak J Med Sci. 2020;36(Covid19-s4):S85-s9. doi: 10.12669/pjms.36.COVID19-S4.2784. PubMed PMID: 32582320.
136. Sidor A, Rzymski P. Dietary Choices and Habits during COVID-19 Lockdown: Experience from Poland. Nutrients. 2020;12(6). doi: 10.3390/nu12061657. PubMed PMID: 32503173.
137. Bhatia V, Mandal P, Satyanarayana S, Aditama T, Sharma M. Mitigating the impact of the COVID-19 pandemic on progress towards ending tuberculosis in the WHO South-East Asia Region. WHO South-East Asia Journal of Public Health. 2020;9(2):95-9. doi: 10.4103/2224-3151.294300.
138. Dieppe A, Kose MA. The Global Productivity Slump: What Policies to Rekindle? (https://www.brookings.edu/research/the-global-productivity-slump-what-policies-to-rekindle/#footnote-2). Washington DC: 2020.
139. Naidoo R, Fisher B. Reset Sustainable Development Goals for a pandemic world. Nature. 2020;583(7815):198-201. Epub 2020/07/08. doi: 10.1038/d41586-020-01999-x. PubMed PMID: 32632244.
140. Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M, et al. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet. 2020;395(10231):1175-7. PubMed PMID: 32278371.
141. UNFPA, Avenir Health, Johns Hopkins University, Victoria University. Impact of the COVID-19 Pandemic on Family Planning and Ending Gender-based Violence, Female Genital Mutilation and Child Marriage. Pandemic threatens achievement of the Transformative Results committed to by UNFPA. https://www.unfpa.org/sites/default/files/resource-pdf/COVID-19_impact_brief_for_UNFPA_24_April_2020_1.pdf: UNFPA, April, 2020.
142. Kumar N. COVID 19 era: a beginning of upsurge in unwanted pregnancies, unmet need for contraception and other women related issues. Eur J Contracept Reprod Health Care. 2020;25(4):323-5. doi: 10.1080/13625187.2020.1777398. PubMed PMID: 32567961.
143. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018;392(10144):312-58. Epub 2018/07/24. doi: 10.1016/s0140-6736(18)31070-5. PubMed PMID: 30032975; PubMed Central PMCID: PMCPMC6323648.
144. Zuckerman G, McKay B. How HIV Research Laid the Foundation for COVID Vaccines. Wall Street Journal. 2020.
145. amfAR. The Broad Benefits of AIDS Research. New York, NY: 2020.
146. WHO. TB and HIV, and other comorbidities 2020. Available from: https://www.who.int/tb/areas-of-work/tb-hiv/en/#:~:text=TB%20is%20the%20most%20common,HIV%2Dassociated%20TB%20in%202018.

147. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply. Journal of studies on alcohol and drugs. 2020;81(5):556-60. Epub 2020/10/09. PubMed PMID: 33028465.
148. Pérez-Escamilla R, Cunningham K, Moran VH. COVID-19 and maternal and child food and nutrition insecurity: a complex syndemic. Maternal & child nutrition. 2020;16(3):e13036. Epub 2020/05/28. doi: 10.1111/mcn.13036. PubMed PMID: 32458574; PubMed Central PMCID: PMCPMC7267083.
149. Poteat T, Millett GA, Nelson LE, Beyrer C. Understanding COVID-19 risks and vulnerabilities among black communities in America: the lethal force of syndemics. Annals of epidemiology. 2020;47:1-3. Epub 2020/05/19. doi: 10.1016/j.annepidem.2020.05.004. PubMed PMID: 32419765; PubMed Central PMCID: PMCPMC7224650.
150. Venkatesh V. Impacts of COVID-19: A research agenda to support people in their fight. International journal of information management. 2020;55:102197. Epub 2020/08/25. doi: 10.1016/j.ijinfomgt.2020.102197. PubMed PMID: 32836648; PubMed Central PMCID: PMCPMC7368151.
151. Queiroz MM, Ivanov D, Dolgui A, Fosso Wamba S. Impacts of epidemic outbreaks on supply chains: mapping a research agenda amid the COVID-19 pandemic through a structured literature review. Annals of operations research. 2020:1-38. Epub 2020/08/25. doi: 10.1007/s10479-020-03685-7. PubMed PMID: 32836615; PubMed Central PMCID: PMCPMC7298926.
152. Oyebode O, Ramsay SE, Brayne C. Public health research in the UK to understand and mitigate the impact of COVID-19 and COVID-19 response measures. Journal of epidemiology and community health. 2020. Epub 2020/10/09. doi: 10.1136/jech-2020-214997. PubMed PMID: 33028615.
153. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective. AIDS Behav. 2020;24(8):2244-9. Epub 2020/04/19. doi: 10.1007/s10461-020-02871-9. PubMed PMID: 32303925; PubMed Central PMCID: PMCPMC7165075.
154. Yadav UN, Rayamajhee B, Mistry SK, Parsekar SS, Mishra SK. A Syndemic Perspective on the Management of Non-communicable Diseases Amid the COVID-19 Pandemic in Low- and Middle-Income Countries. Frontiers in public health. 2020;8:508. Epub 2020/10/27. doi: 10.3389/fpubh.2020.00508. PubMed PMID: 33102414; PubMed Central PMCID: PMCPMC7545493.
155. Hollingsworth TD. Controlling infectious disease outbreaks: Lessons from mathematical modelling. J Public Health Policy. 2009;30(3):328-41. Epub 2009/10/07. doi: 10.1057/jphp.2009.13. PubMed PMID: 19806073; PubMed Central PMCID: PMCPMC7099230.
156. Viboud C, Sun K, Gaffey R, Ajelli M, Fumanelli L, Merler S, et al. The RAPIDD ebola forecasting challenge: Synthesis and lessons learnt. Epidemics. 2018;22:13-21. Epub 2017/09/30. doi: 10.1016/j.epidem.2017.08.002. PubMed PMID: 28958414; PubMed Central PMCID: PMCPMC5927600.
157. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al. Key questions for modelling COVID-19 exit strategies. Proc Biol Sci. 2020;287(1932):20201405. Epub 2020/08/13. doi: 10.1098/rspb.2020.1405. PubMed PMID: 32781946; PubMed Central PMCID: PMCPMC7575516.

158. Development. OfECa. Health Care Resources: Hospital Beds (https://stats.oecd.org/index.aspx?queryid=30183). 2020.
159. Scheffler R. The Labour market for human resources for health in low- and middle-income countries (https://www.who.int/hrh/resources/Observer11_WEB.pdf). Geneva: 2012.
160. WHO. Global Health Observatory data repository (https://apps.who.int/gho/data/node.main.MHHR?lang=en). Geneva: 2019.
161. Carias C, Pawaskar M, Nyaku M, Conway JH, Roberts CS, Finelli L, et al. Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US). Vaccine. 2020. Epub 2020/12/19. doi: 10.1016/j.vaccine.2020.11.074. PubMed PMID: 33334618; PubMed Central PMCID: PMCPMC7723783.
162. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al. Impact of the COVID-19 Pandemic on Emergency Department Visits - United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699-704. Epub 2020/06/12. doi: 10.15585/mmwr.mm6923e1. PubMed PMID: 32525856; PubMed Central PMCID: PMCPMC7315789 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
163. Dyer O. Covid-19: Pandemic is having "severe" impact on non-communicable disease care, WHO survey finds. BMJ. 2020;369:m2210. Epub 2020/06/05. doi: 10.1136/bmj.m2210. PubMed PMID: 32493728.
164. Strully K, Yang TC, Liu H. Regional variation in COVID-19 disparities: connections with immigrant and Latinx communities in U.S. counties. Ann Epidemiol. 2021;53:56-62 e2. Epub 2020/09/15. doi: 10.1016/j.annepidem.2020.08.016. PubMed PMID: 32927056; PubMed Central PMCID: PMCPMC7485497.
165. Noman AHM, Griffiths MD, Pervin S, Ismail MN. The detrimental effects of the COVID-19 pandemic on domestic violence against women. J Psychiatr Res. 2020;134:111-2. Epub 2021/01/01. doi: 10.1016/j.jpsychires.2020.12.057. PubMed PMID: 33383493.
166. Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A systematic review and meta-analysis. PLoS One. 2020;15(12):e0244630. Epub 2020/12/29. doi: 10.1371/journal.pone.0244630. PubMed PMID: 33370404.

APPENDIX: Search Strategies

HIV

(((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] : "3000/MM/DD"[PDAT]))) AND ("HIV"[Mesh] OR "Acquired Immunodeficiency Syndrome"[Mesh] OR "HIV Infections"[Mesh] OR human immunodeficiency virus*[tw] OR acquired immunodeficiency syndrome*[tw] OR HIV*[tw] OR "AIDS"[tw] OR HIV1*[tw] OR HIV2*[tw])

Malnutrition

(((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] : "3000/MM/DD"[PDAT]))) AND ("Infant nutrition disorders"[Mesh] OR "child nutrition disorders"[Mesh] OR "malnutrition"[Mesh] OR "thinness"[Mesh] OR "wasting syndrome" [Mesh] OR "undernutrition"[tw] OR undernourish*[tw] OR "chronic energy deficiency"[tw] OR "stunting"[tw] OR "wasting"[tw] OR "underweight"[tw] OR "thinness"[tw] OR micronutrient deficienc*[tw] OR vitamin deficienc*[tw] OR mineral deficienc*[tw])

Malaria

(((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] : "3000/MM/DD"[PDAT]))) AND ("Malaria" [Mesh] OR "malaria" [tw] OR "plasmodium" [tw])

TB

(((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] : "3000/MM/DD"[PDAT]))) AND ("Tuberculosis" [Mesh] OR "tuberculosis" [tw] OR "TB"[tw] OR mycobacter*[tw])

Sexual and Reproductive Health

((("COVID-19"[tw] OR "COVID 19"[tw] OR "COVID19"[tw] OR "COVID2019"[tw] OR "COVID 2019"[tw] OR "COVID-2019"[tw] OR "novel coronavirus"[tw] OR "new coronavirus"[tw] OR "novel corona virus"[tw] OR "new corona virus"[tw] OR "SARS-CoV-2"[tw] OR "SARSCoV2"[tw] OR "SARS-CoV2"[tw] OR "2019nCoV"[tw] OR "2019-nCoV"[tw] OR "2019 coronavirus"[tw] OR "2019 corona virus"[tw] OR "coronavirus disease 2019"[tw] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "severe acute respiratory syndrome coronavirus 2"[tw] OR "sars-coronavirus-2"[tw] OR "coronavirus disease 2019"[tw] OR "corona virus disease 2019"[tw])) AND (("2020/MM/DD"[PDAT] : "3000/MM/DD"[PDAT]))) AND ("Reproductive Health" [Mesh] OR "Reproductive Health Services"[Mesh] OR “maternal health”[Mesh] OR “maternal health services”[Mesh] OR "reproductive health"[tw] “maternal health”[tw] OR contracept*[tw] OR "family planning"[tw] OR "abortion"[tw] OR "post-abortion care"[tw] OR "unintended pregnancy"[tw] OR “unplanned pregnancy”[tw] OR “unwanted pregnancy”[tw])